RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Inclusion Criteria: * Histologically confirmed locally advanced or metastatic thyroid cancer, excluding thyroid lymphomas not amenable to or refractory to surgical resection, external beam radiotherapy, radioiodine or other local therapies. * Prior therapy with chemotherapy and targeted therapies except for mTor inhibitors is allowed. * Medullary thyroid cancer with documented evidence of disease progression by modified RECIST within 6 months before study day 1 or symptomatic disease at the time of screening in the absence of documented disease progression. * Differentiated thyroid cancer with documented evidence of disease progression by modified RECIST within 6 months before study day 1. * Anaplastic thyroid cancer with disease progression with documented disease progression by modified RECIST within 6 months of study day 1. * Patients must have at least one measurable site of disease according to RECIST criteria that has not previously irradiated. If the patient has has previous radiation to the marker lesion(s), there must be evidence of progression since radiation. * 18 years of age or older * WHO performance status 2 or less * Adequate bone marrow, liver, and renal function * Fasting serum cholesterol 300mg/dL or less OR 7.75 mmol/L or less AND fasting triglycerides 2.5x ULN or less Exclusion Criteria: * Patients receiving anticancer therapies within last 2 weeks or who have received radiation therapy within 3 weeks of study day 1 * Prior therapy with mTOR inhibitors…